Canary Staked INJ ETF

S-1/A amended

The current S-1/A filing for the Canary Staked INJ ETF outlines operational agreements and risk disclosures. Key components include the Transfer Agency and Service Agreement with U.S. Bancorp Fund Services, LLC, the Cash Custody Agreement, and the Index License Agreement with CoinDesk. The filing emphasizes the ETF's reliance on third-party service providers for critical functions like share creation/redemption, asset custody, and index data. It also details termination clauses, liability limitations, and indemnification provisions for these agreements. The document highlights tax implications for U.S. and non-U.S. shareholders and addresses risks related to the Injective Network's security and governance.

S-1/A amended

Price $25.00

The filing outlines the creation and redemption processes for the Canary Staked INJ ETF, detailing procedures for purchase orders, redemption, and transaction fees. It emphasizes the Trust's reliance on the Injective Network's blockchain security and highlights risks related to network vulnerabilities, airdrop policies, and market volatility. The document also addresses the Sponsor's discretion in managing creation/redemption activities and potential impacts on secondary market pricing.

S-1/A amended

The Canary Staked INJ ETF (the Trust) is an exchange-traded product designed to provide exposure to the price of Injective (INJ) held by the Trust, with a secondary objective of earning staking rewards through participation in the Injective network's proof-of-stake blockchain. The Trust will list shares on the Cboe BZX Exchange, with shares redeemable in blocks of 10,000. The Trust is structured with a Sponsor (Canary Capital Group LLC), Trustee (CSC Delaware Trust Company), Custodian (BitGo Trust Company, Inc.), and Transfer Agent (U.S. Bancorp Fund Services, LLC). The Trust is not regulated under the Investment Company Act of 1940 and does not offer the same protections as traditional funds.

S-1 filed

Canary Staked INJ ETF (the Trust) is an exchange-traded product seeking to provide exposure to the price of Injective (INJ) cryptocurrency, less operational expenses, while earning staking rewards through the Injective blockchain. The Trust is sponsored by Canary Capital Group LLC and structured as an emerging growth company. It will issue shares traded on an exchange, with no prior public market for its securities. The offering is registered under the Securities Act of 1933, but the Trust is not subject to regulation under the Investment Company Act of 1940, lacking certain investor protections.